Attralus

Attralus is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, developing transformative medicines for patients with systemic amyloidosis. Its proprietary pan-amyloid removal (PAR) platform pairs a pan-amyloid binding peptide with a humanized IgG1 monoclonal antibody so the resulting fusion protein binds amyloid deposits across every amyloidosis type and stage and recruits the immune system to clear them. The lead candidate, zamubafusp alfa (AT-02), is a pan-amyloid depleter in a Phase 1/2 open-label extension study and has received U.S. FDA Orphan Drug Designation for the treatment of AL amyloidosis; a next-generation PAR program (IV and subcutaneous) and a research-stage neurodegeneration program targeting Abeta, tau and alpha-synuclein aggregates follow behind it. Attralus' molecular imaging agents AT-01 (124-iodine evuzamitide) and AT-05 (99mTc-p5+14) were acquired by Bayer in January 2026. The company was launched in 2020 with a Series A from venBio Partners and has since raised additional rounds including a $56 million financing led by Alpha Wave Ventures with participation from Bristol Myers Squibb. Attralus is a therapeutics developer, not a software vendor: it publishes no developer portal, no public API, no SDKs and no machine-readable API contract of any kind (every OpenAPI, GraphQL, MCP, A2A and /.well-known/ path probed on its hosts returns 404, and no api/developer/docs subdomain resolves).

Attralus is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Health.

Attralus’ developer surface includes support and 17 more developer resources.

🌐 Visit website 📡 Source on GitHub
12.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesHealthClinical TrialsTherapeuticsRare DiseaseAmyloidosisMonoclonal AntibodiesMolecular ImagingNeurodegenerationDrug Development

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1
Composite quality — 12.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.9 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.9 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/attralus: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Attralus Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt
LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Contact
Contact
 Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService
TermsOfService
 PrivacyPolicy
PrivacyPolicy

Company 7

The organization behind the API

Website
Website
 About
About
 Press
Press
 PressRSS
PressRSS
 Careers
Careers
 LinkedIn
LinkedIn
 Twitter
Twitter

Scroll for all 7

Other 5

Properties that don't map to a standard resource type

SecondaryMarket
SecondaryMarket
 Science
Science
 Pipeline
Pipeline
 Resources
Resources
 Publications
Publications

Source (apis.yml)

apis.yml Raw ↑ 
aid: attralus
name: Attralus
description: 'Attralus is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, developing
  transformative medicines for patients with systemic amyloidosis. Its proprietary pan-amyloid removal (PAR) platform pairs
  a pan-amyloid binding peptide with a humanized IgG1 monoclonal antibody so the resulting fusion protein binds amyloid deposits
  across every amyloidosis type and stage and recruits the immune system to clear them. The lead candidate, zamubafusp alfa
  (AT-02), is a pan-amyloid depleter in a Phase 1/2 open-label extension study and has received U.S. FDA Orphan Drug Designation
  for the treatment of AL amyloidosis; a next-generation PAR program (IV and subcutaneous) and a research-stage neurodegeneration
  program targeting Abeta, tau and alpha-synuclein aggregates follow behind it. Attralus'' molecular imaging agents AT-01
  (124-iodine evuzamitide) and AT-05 (99mTc-p5+14) were acquired by Bayer in January 2026. The company was launched in 2020
  with a Series A from venBio Partners and has since raised additional rounds including a $56 million financing led by Alpha
  Wave Ventures with participation from Bristol Myers Squibb. Attralus is a therapeutics developer, not a software vendor:
  it publishes no developer portal, no public API, no SDKs and no machine-readable API contract of any kind (every OpenAPI,
  GraphQL, MCP, A2A and /.well-known/ path probed on its hosts returns 404, and no api/developer/docs subdomain resolves).'
url: https://raw.githubusercontent.com/api-evangelist/attralus/refs/heads/main/apis.yml
image: https://attralus.com/wp-content/uploads/2023/03/logo-color.png
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Health
- Clinical Trials
- Therapeutics
- Rare Disease
- Amyloidosis
- Monoclonal Antibodies
- Molecular Imaging
- Neurodegeneration
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://attralus.com/
- type: SecondaryMarket
  url: https://forgeglobal.com/attralus_stock/
- type: About
  url: https://attralus.com/company
- type: Science
  url: https://attralus.com/science
- type: Pipeline
  url: https://attralus.com/pipeline
- type: Resources
  url: https://attralus.com/amyloidosis
- type: Press
  url: https://attralus.com/press-releases
- type: PressRSS
  url: https://attralus.com/feed/
- type: Publications
  url: https://attralus.com/posters-and-publications
- type: Careers
  url: https://attralus.com/careers
- type: Contact
  url: https://attralus.com/contact
- type: Support
  url: https://attralus.com/contact
- type: TermsOfService
  url: https://attralus.com/terms-of-service
- type: PrivacyPolicy
  url: https://attralus.com/privacy-policy
- type: LinkedIn
  url: https://www.linkedin.com/company/attralus/
- type: Twitter
  url: https://x.com/attralus
- type: LLMsTxt
  url: llms/attralus-llms.txt
- type: DomainSecurity
  url: security/attralus-domain-security.yml
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 2
  pass: local-v1